CLINICAL TRIALS PROFILE FOR ALTOPREV

All Clinical Trials for ALTOPREV

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00285857 ↗	Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention	Terminated	Stanford University	Phase 2	2005-11-01	The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
NCT00302952 ↗	Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis	Terminated	Autoimmunity Centers of Excellence	Phase 2	2007-11-06	Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. The purpose of this study is to determine the safety and effectiveness of lovastatin for controlling inflammation in mildly active RA.
NCT00302952 ↗	Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2007-11-06	Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. The purpose of this study is to determine the safety and effectiveness of lovastatin for controlling inflammation in mildly active RA.
NCT00580970 ↗	Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury	Completed	Hunter Holmes Mcguire Veteran Affairs Medical Center	Phase 2	2007-04-01	Lovastatin may protect against late effects of radiation therapy in patients with prostate cancer
NCT00580970 ↗	Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury	Completed	Virginia Commonwealth University	Phase 2	2007-04-01	Lovastatin may protect against late effects of radiation therapy in patients with prostate cancer
NCT00583102 ↗	Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML	Terminated	University of Iowa	Phase 1/Phase 2	2001-06-01	The purpose of this study is to test the safety and effectiveness of combining a drug known as Lovastatin to the chemotherapy drug cytarabine. Lovastatin is currently used to lower blood cholesterol levels and lab data suggests that it increases the anti-leukemia activity of cytarabine. This research is being done because high doses of cytarabine induce remissions in only about 25% of patients with acute myeloid leukemia.
NCT00585052 ↗	A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer	Terminated	University of Iowa	Phase 2	2003-08-01	The purpose of this study is to find out if the treatment combination of paclitaxel and lovastatin is more effective than the currently available chemotherapy for refractory or relapsed ovarian cancer. This research is being done to improve on currently available chemotherapy for ovarian cancer.

Clinical Trial Conditions for ALTOPREV

Condition Name

Condition Name for ALTOPREV
Intervention	Trials
Acute Myeloid Leukemia	1
Breast Cancer	1
Hyperlipidemias	1
Ovarian Cancer	1

Condition MeSH

Condition MeSH for ALTOPREV
Intervention	Trials
Leukemia	1
Hyperlipoproteinemias	1
Prostatic Neoplasms	1
Hyperlipidemias	1

Clinical Trial Locations for ALTOPREV

Trials by Country

Trials by Country for ALTOPREV
Location	Trials
United States	17

Trials by US State

Trials by US State for ALTOPREV
Location	Trials
California	2
Iowa	2
Oklahoma	1
North Carolina	1
New York	1

Clinical Trial Progress for ALTOPREV

Clinical Trial Phase

Clinical Trial Phase for ALTOPREV
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	4
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for ALTOPREV
Clinical Trial Phase	Trials
Terminated	4
Completed	1
Recruiting	1

Clinical Trial Sponsors for ALTOPREV

Sponsor Name

Sponsor Name for ALTOPREV
Sponsor	Trials
University of Iowa	2
Hunter Holmes Mcguire Veteran Affairs Medical Center	1
Virginia Commonwealth University	1

Sponsor Type

Sponsor Type for ALTOPREV
Sponsor	Trials
Other	6
U.S. Fed	1
Industry	1